Literature DB >> 18716370

Defective phosphatidylinositol 3-kinase signaling in central control of cardiovascular effects in the nucleus tractus solitarii of spontaneously hypertensive rats.

Michael Hsiao1, Pei-Jung Lu, Hsiao-Ning Huang, Wan-Chen Lo, Wen-Yu Ho, Tsung-Ching Lai, Hung-Ting Chiang, Ching-Jiunn Tseng.   

Abstract

Recently we have shown functional involvement of the phosphatidylinositol 3-kinase (PI3K)-Akt-nitric oxide synthase (NOS) signaling pathway in central control of cardiovascular effects in the nucleus tractus solitarii (NTS) of normotensive Wistar-Kyoto (WKY) rats. In this study we determined whether PI3K/Akt signaling was defective in spontaneously hypertensive rats (SHR). WKY rats and SHR were anesthetized with urethane. Mean blood pressure (MBP) and heart rate (HR) were monitored intra-arterially. Unilateral microinjection (60 nL) of insulin (100 IU/mL) into the NTS produced prominent depressor and bradycardic effects in 8- and 16-week-old normotensive WKY and 8-week-old SHR. However, no significant cardiovascular effects were found in 16-week-old SHR after insulin injection. Furthermore, pretreatment with PI3K inhibitor LY294002 and NOS inhibitor L-NAME into the NTS attenuated the cardiovascular response evoked by insulin in WKY and 8-week-old SHR but not in 16-week-old SHR. Unilateral microinjection of 1 mmol/L of PI(3,4,5)P(3) (phosphatidylinositol 3,4,5-triphosphate), a phospholipids second messenger produced by PI3K, into the NTS produced prominent depressor and bradycardic effects in 8- or 16-week-old WKY rats as well as 8-week-old SHR but not in 16-week-old SHR. Western blot analysis showed no significant increase in Akt phosphorylation in 8-week-old pre-hypertensive SHR after insulin injection. Similar results were also found in hypertensive 16-week-old SHR. Our results indicate that the Akt-independent signaling pathway is involved in NOS activation to regulate cardiovascular effects in the NTS of 8-week-old pre-hypertensive SHR. Both Akt-dependent and Akt-independent signaling pathways are defective in hypertensive 16-week-old SHR.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18716370     DOI: 10.1291/hypres.31.1209

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  5 in total

1.  Central nicotinic acetylcholine receptor involved in Ca(2+) -calmodulin-endothelial nitric oxide synthase pathway modulated hypotensive effects.

Authors:  Pei-Wen Cheng; Pei-Jung Lu; Siang-Ru Chen; Wen-Yu Ho; Wen-Han Cheng; Ling-Zong Hong; Tung-Chen Yeh; Gwo-Ching Sun; Ling-Lin Wang; Michael Hsiao; Ching-Jiunn Tseng
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

2.  Shift to an involvement of phosphatidylinositol 3-kinase in angiotensin II actions on nucleus tractus solitarii neurons of the spontaneously hypertensive rat.

Authors:  Chengwen Sun; Jasenka Zubcevic; Jaimie W Polson; Jeffrey T Potts; Carlos Diez-Freire; Qi Zhang; Julian F R Paton; Mohan K Raizada
Journal:  Circ Res       Date:  2009-10-22       Impact factor: 17.367

3.  Chronic blockade of phosphatidylinositol 3-kinase in the nucleus tractus solitarii is prohypertensive in the spontaneously hypertensive rat.

Authors:  Jasenka Zubcevic; Hidefumi Waki; Carlos Diez-Freire; Alexandra Gampel; Mohan K Raizada; Julian F R Paton
Journal:  Hypertension       Date:  2008-11-17       Impact factor: 10.190

4.  The Impact of Insulin Resistance on Cardiovascular Control During Exercise in Diabetes.

Authors:  Masaki Mizuno; Norio Hotta; Rie Ishizawa; Han-Kyul Kim; Gary Iwamoto; Wanpen Vongpatanasin; Jere H Mitchell; Scott A Smith
Journal:  Exerc Sport Sci Rev       Date:  2021-07-01       Impact factor: 6.642

5.  Rhynchophylline Ameliorates Endothelial Dysfunction via Src-PI3K/Akt-eNOS Cascade in the Cultured Intrarenal Arteries of Spontaneous Hypertensive Rats.

Authors:  Hui-Feng Hao; Li-Mei Liu; Chun-Shui Pan; Chuan-She Wang; Yuan-Sheng Gao; Jing-Yu Fan; Jing-Yan Han
Journal:  Front Physiol       Date:  2017-11-15       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.